FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza
October 24, 2018 — Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
“This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical. This novel drug provides an important, additional treatment option,” said FDA Commissioner Scott Gottlieb, M.D. “While there are several FDA-approved antiviral drugs to treat flu, they’re not a substitute for yearly vaccination. Flu season is already well underway, and the U.S. Centers for Disease Control and Prevention recommends getting vaccinated by the end of October, as seasonal flu vaccine is one of the most effective and safest ways to protect yourself, your family and your community from the flu and serious flu-related complications, which can result in hospitalizations. Yearly vaccination is the primary means of preventing and controlling flu outbreaks.”
Flu is a contagious respiratory illness caused by influenza viruses. When patients with the flu are treated within 48 hours of becoming sick, antiviral drugs can reduce symptoms and duration of the illness.
“When treatment is started within 48 hours of becoming sick with flu symptoms, antiviral drugs can lessen symptoms and shorten the time patients feel sick,” said Debra Birnkrant, M.D., director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research. “Having more treatment options that work in different ways to attack the virus is important because flu viruses can become resistant to antiviral drugs.”
The safety and efficacy of Xofluza, an antiviral drug taken as a single oral dose, was demonstrated in two randomized controlled clinical trials of 1,832 patients where participants were assigned to receive either Xofluza, a placebo, or another antiviral flu treatment within 48 hours of experiencing flu symptoms. In both trials, patients treated with Xofluza had a shorter time to alleviation of symptoms compared with patients who took the placebo. In the second trial, there was no difference in the time to alleviation of symptoms between subjects who received Xofluza and those who received the other flu treatment.
The most common adverse reactions in patients taking Xofluza included diarrhea and bronchitis.
Xofluza was granted Priority Review under which the FDA’s goal is to take action on an application within an expedited time frame where the agency determines that the drug, if approved, would significantly improve the safety or effectiveness of treating, diagnosing or preventing a serious condition.
The FDA granted approval of Xofluza to Shionogi & Co., Ltd.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Posted: October 2018
Xofluza (baloxavir marboxil) FDA Approval History
November 13, 2018
- CityU develops first microarrayed 3D neuronal culture platform
- Expert suggests ways to control uncomfortable vaginal symptoms in diabetic women
- New edition of Red Journal focuses on roles of imaging in radiation oncology
- Doctors Aren’t Promoting Breastfeeding’s Cancer-Protection Benefit
- Technique to ‘listen’ to a patient’s brain during tumour surgery
- Seven-year-old returns to life as a “normal, healthy child” following bone marrow transplant
- AMSBIO expands range of high quality FFPE cancer cell line controls
- Exploring NMR Spectroscopy Applications through Interesting Infographics
- Chapman University wins additional $2.9 million NIH grant to study Alzheimer’s disease
- Microgel powder reduces infection and promotes healing
- Suicidal patients with prescribed access to psychotropic drugs should be closely monitored
- Nitric oxide-releasing technology shows potential to reduce healing time of diabetic foot ulcers
- Mass shootings may trigger unnecessary blood donations
- From heart disease to cancer: New study tracks shift of county death rates
- Preventing falls with new sensor technology
- Promising technology could improve detection, diagnosis of fatal ovarian cancer
- AAP updates concussion recommendations for children and teens
- Two genomic tests help identify most effective treatment for breast cancer patients
- Researchers evaluate efficacy of salivary biomarkers for early detection of oral cancer
- NIH awards $3.5 million to continue development of robotic system for treating brain tumors